Please login to the form below

Not currently logged in
Email:
Password:

GSK appoints rare diseases research head

Birgitte Volck moves to the company from Swedish Ophan Biovitrum

GSK Sobi Birgitte VolckGlaxoSmithKline has appointed Birgitte Volck has its new head of rare diseases R&D.

She will join GSK after working her six months notice at Swedish Ophan Biovitrum (Sobi), which she joined four years ago and where she served as its chief medical officer.

Sobi's president and CEO Geoffrey McDonough said: "We thank Birgitte for her leadership and dedication which has helped to evolve Sobi's patient oriented research and development organisation into a highly skilled international team.

"Birgitte joined Sobi in 2012 and has been instrumental in advancing Sobi's late stage development projects and in bringing new treatment options to people with rare diseases."

Prior to joining Stockholm-based Sobi Volck spent five years at Amgen, where she served as executive development director, bone, neuroscience and inflammation, international R&D.

Before Amgen she held positions with Genzyme as Nordic medical director and project director and at Denmark's Pharmexa as vice president, clinical development and medical affairs.

15th January 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

#DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
In our recent Demand Diversity research, a Black American participant said, “I wish people were more educated. Doctors are supposed to treat everyone the same, not have favourites. They need...
JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...